PEDIATRICS Vol. 63 No. 5 May 1979, pp. 741-746
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wall, M. A.
Right arrow Articles by Strieder, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wall, M. A.
Right arrow Articles by Strieder, D. J.

Lung Function in Adolescents Receiving High-Dose Methotrexate

Michael A. Wall M.D.1, Mary Ellen B. Wohl M.D.1, Norman Jaffe M.D.1, and Denise J. Strieder M.D.1

1 Department of Medicine (Pulmonary Division), Children's Hospital Medical Center, the Sidney Farber Cancer Institute, and the Department of Pediatrics, Harvard Medical School, Boston

Methotrexate (MTX) has been implicated as a cause of interstitial pneumonitis and/or fibrosis, but the mechanism by which the drug causes these processes is not known. The purpose of this study was to determine whether patients receiving high-dose MTX developed a consistent decrease in pulmonary function, which would implicate a role for total dose of MTX received in the pathogenesis of the lung toxicity. Pulmonary function studies, including spirometry, plethysmography, and diffusing capacity at two levels of alveolar Po2, were performed in 38 adolescents treated for osteogenic sarcoma. The patients were divided into three groups including 12 patients (group 1) studied before and during therapy, 15 patients (group 2) studied during therapy, and 11 patients (group 3) studied after completion of treatment. While total dose received at the time of the study varied from 0 to 256 gm/sq m, pulmonary function showed no change, with one exception. A mild restrictive defect and decrease in diffusing capacity due to unilateral pleural and diaphragmatic disease, whose relationship to MTX therapy is uncertain, developed in one patient. MTX, when administered in high dose to young patients by the described protocol, causes no dose-related decrease in pulmonary function.

Accepted on June 15, 1978




This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
J. K. Dawson and M. P. Lynch
Reply
Rheumatology, June 1, 2003; 42(6): 803 - 804.
[Full Text] [PDF]